Cipla Q4 Profit Falls 55% to ₹555 crore; declares ₹13/sh dividend
Cipla Q4 Profit Falls 55% to ₹555 crore; declares ₹13/sh dividend
Cipla reports a sharp 55% YoY drop in Q4 net profit to ₹555 crore, trims revenue, and approves a final dividend of ₹13 per share for FY26.
Cipla Ltd on Wednesday reported a 55% year-on-year decline in its consolidated net profit for the fourth quarter, at ₹555 crore, down from ₹1,222 crore in the year-ago quarter. The board has recommended a final dividend of ₹13 per share for FY26, with the record date set at June 5.
Revenue from operations in the quarter fell 3% YoY to ₹6,541 crore, while EBITDA declined 35% to ₹997 crore, resulting in an EBITDA margin of 15.2% compared with 22.8% a year earlier. For the full financial year FY26, Cipla posted revenue of ₹28,163 crore, up 2% YoY, but net profit (PAT) declined 26% to ₹3,879 crore from ₹5,273 crore in FY25. EBITDA for the year slipped 17% to ₹5,925 crore, with margins narrowing to 21% from 25.9% last year.
Geographically, the One India business remained a key growth driver, expanding 15% YoY to ₹3,007 crore in Q4 FY26. Branded prescription therapies, including respiratory, urology, anti-diabetes and cardiac segments, continued to post strong growth, while consumer health brands such as Nicotex, Omnigel and Cipladine maintained leadership positions. North America revenue, however, came under pressure, slipping 26% YoY to ₹1,414 crore despite regulatory progress, including the approval for the first AB-rated generic version of gVentolin manufactured from Cipla’s US facility. The One Africa business delivered robust momentum, with quarterly revenue rising 21% YoY to ₹1,236 crore and South Africa up 33% to ₹984 crore. Emerging Markets and Europe revenue declined 9% YoY amid geopolitical uncertainties. Cipla reiterated that India remains a key growth driver for the quarter and highlighted ongoing regulatory and market dynamics across its global portfolio.
Overall, the quarter reflects a challenging external environment, even as the company pursues new approvals and markets to offset soft spots in North America and parts of Europe. The dividend suggestion underscores a continued commitment to shareholder returns despite profit volatility.
